The Valens Company Reports Financial Results for the Third Quarter of Fiscal 2020

KELOWNA, BC, Oct. 14, 2020 /CNW/ – The Valens Company Inc.  (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to report its third quarter financial results for the period ended August 31, 2020. Key Financial Highlights Net revenue for the third quarter of 2020 was $18.1 million, aContinue reading “The Valens Company Reports Financial Results for the Third Quarter of Fiscal 2020”

Flower One Announces Preliminary Q3 2020 Revenue of $11.5 Million, Exceeding Guidance for the Quarter

LAS VEGAS and TORONTO, Oct. 13, 2020 /CNW/ – Flower One Holdings Inc. (the “Company”) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), a leading cannabis cultivator, producer and innovator in Nevada, today announced preliminary third quarter revenue of $11.5 million surpassing its Q3 2020 revenue guidance range of between $9.8 million and $10.8 million.  The Company continues to expect its Q3 2020 gross margin to be inContinue reading “Flower One Announces Preliminary Q3 2020 Revenue of $11.5 Million, Exceeding Guidance for the Quarter”

Organigram Reports Third Quarter Fiscal 2020 Results

Net revenue of $18.0 million compared to $24.8 million in Q3 2019 Generated positive cash flow from operations of $8.5 million as a result of monetization and optimization of working capital and ended the quarter with cash and short-term investments of $44.8 million Subsequent to quarter-end, raised $17.9 million in gross proceeds to complete theContinue reading “Organigram Reports Third Quarter Fiscal 2020 Results”

HEXO Corp. reports third quarter fiscal 2020 financial results; Net Revenue Up 30% to $22.1 Million, Improved Operational Performance

Key Operating Highlights Gross Revenue increased 30% to $30.9M from $23.8M in Q2 Net Revenue increased 30% to $22.1M from $17.0M in Q2 Adult-use grams and gram equivalents sold increased 42% to 9,338 kg compared to Q2 Gross Margins increased to 40% Operating expenses decreased to $26.8M Closed $46M public offering to enhance liquidity AdjustedContinue reading “HEXO Corp. reports third quarter fiscal 2020 financial results; Net Revenue Up 30% to $22.1 Million, Improved Operational Performance”

Chemesis International Inc. Reports Q3 2020 Financial Statements

VANCOUVER, BC / ACCESSWIRE / June 2, 2020 / Chemesis International Inc. (CSE:CSI) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announced its financial results for the third quarter of 2020 ended March 31, 2020. Unless otherwise stated, all references to currency are in CDN dollars. Third Quarter 2020 Financial & Operational Highlights Revenues of $4,529,524 and gross profit marginContinue reading “Chemesis International Inc. Reports Q3 2020 Financial Statements”

Supreme Cannabis Announces Q3 2020 Financial Results

Realigned and rightsized operating model delivers immediate cost savings, reducing quarter-over-quarter operating expenses by 23% excluding restructuring charges Increased recreational sales revenue by 245% year-over-year, grew recreational sales volumes by 26% quarter-over-quarter and is accelerating revenue generation with over 30 SKUs in provinces across Canada, new product launches and an enhanced retail distribution model Maintains a strongContinue reading “Supreme Cannabis Announces Q3 2020 Financial Results”

Aurora Cannabis Announces Fiscal Third Quarter 2020 Results & Operational Reset Update

Net revenue of $78.4 million, excluding provisions of $2.9 million, an increase of 18% over prior quarter Consumer cannabis net revenue of $41.5 million, excluding provisions, a 24% increase over prior quarter Cash cost to produce per gram of dried cannabis sold at $0.85, down from $0.88 in Q2 2020 Operational reset on track to deliver the Company’s commitment to positiveContinue reading “Aurora Cannabis Announces Fiscal Third Quarter 2020 Results & Operational Reset Update”

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER, May 14, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN;OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2020 (“3Q20”) which ended March 31, 2020. Conference Call &Continue reading “InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update”